Highlights
- Market Cap
- $567.64M
- Enterprise Value
- $631.28M
- EPS (TTM)
- $1.63
- PE Ratio
- 19.20
- PEG Ratio
- 0.85
- Total Revenue (TTM)
- $52.15M
- Gross Profit (TTM)
- $49.19M
- EBITDA (TTM)
- $39.93M
- Year Range
- $18.35 - $39.92
- Target Price
- $68.25
- ROA (TTM)
- 10.79%
- ROE (TTM)
- 35.04%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in XOMA Corporation, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
XOMA Corporation (XOMA) has returned 17.98% so far this year and 57.40% over the past 12 months. Over the last ten years, XOMA has returned 7.17% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.
XOMA Corporation
- 1D
- 3.70%
- 1M
- 22.88%
- YTD
- 17.98%
- 6M
- -18.60%
- 1Y
- 57.40%
- 3Y*
- 14.11%
- 5Y*
- -5.05%
- 10Y*
- 7.17%
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Apr 5, 1989, XOMA's average daily return is +0.09%, while the average monthly return is +1.36%. At this rate, your investment would double in approximately 4.3 years.
Historically, 47% of months were positive and 53% were negative. The best month was Dec 2010 with a return of +115.6%, while the worst month was Jul 2015 at -81.2%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 7 months.
On a daily basis, XOMA closed higher 44% of trading days. The best single day was Dec 22, 2010 with a return of +88.3%, while the worst single day was Jul 22, 2015 at -77.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -3.50% | -0.51% | 22.88% | 17.98% | |||||||||
| 2025 | 1.26% | -14.69% | -12.20% | 20.62% | 3.00% | 1.78% | -1.27% | 30.51% | 18.69% | -14.43% | -2.58% | -17.24% | 1.18% |
| 2024 | 7.95% | 21.73% | -1.07% | 5.36% | 1.78% | -8.14% | 12.96% | 9.30% | -9.47% | 14.05% | 10.76% | -21.43% | 42.05% |
| 2023 | 10.27% | 4.88% | -0.80% | -12.88% | -7.56% | 11.12% | -16.62% | -10.98% | 0.50% | 33.78% | -21.27% | 24.66% | 0.54% |
| 2022 | -0.62% | 5.84% | 27.59% | -31.27% | -5.30% | 22.35% | 5.48% | -15.40% | -9.91% | -7.54% | 27.84% | -13.08% | -11.75% |
| 2021 | -17.92% | -0.06% | 12.73% | -6.74% | -22.57% | 15.37% | -4.71% | -3.95% | -20.47% | 1.01% | -17.96% | 1.66% | -52.75% |
Benchmark Metrics
XOMA Corporation has an annualized alpha of 10.28%, beta of 1.17, and R² of 0.06 versus S&P 500 Index. Calculated based on daily prices since April 06, 1989.
- This stock participated in 187.71% of S&P 500 Index downside but only 110.28% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.06 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 10.28%
- Beta
- 1.17
- R²
- 0.06
- Upside Capture
- 110.28%
- Downside Capture
- 187.71%
Return for Risk
Risk / Return Rank
XOMA ranks 69 for risk / return — better than 69% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for XOMA Corporation (XOMA) and compare them to a chosen benchmark (S&P 500 Index).
| XOMA | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.03 | 0.90 | +0.13 |
Sortino ratioReturn per unit of downside risk | 1.56 | 1.39 | +0.17 |
Omega ratioGain probability vs. loss probability | 1.22 | 1.21 | +0.01 |
Calmar ratioReturn relative to maximum drawdown | 1.28 | 1.40 | -0.12 |
Martin ratioReturn relative to average drawdown | 2.73 | 6.61 | -3.87 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore XOMA risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the XOMA Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the XOMA Corporation was 99.96%, occurring on Feb 10, 2017. The portfolio has not yet recovered.
The current XOMA Corporation drawdown is 99.67%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.96% | Mar 6, 1991 | 6536 | Feb 10, 2017 | — | — | — |
| -40.38% | Jan 5, 1990 | 182 | Sep 24, 1990 | 100 | Feb 14, 1991 | 282 |
| -17.2% | Sep 13, 1989 | 13 | Sep 29, 1989 | 64 | Jan 2, 1990 | 77 |
| -12.82% | Jun 19, 1989 | 9 | Jun 29, 1989 | 43 | Aug 30, 1989 | 52 |
| -6.15% | Apr 6, 1989 | 3 | Apr 10, 1989 | 1 | Apr 11, 1989 | 4 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of XOMA Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how XOMA Corporation is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for XOMA, comparing it with other companies in the Biotechnology industry. Currently, XOMA has a P/E ratio of 19.2. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for XOMA compared to other companies in the Biotechnology industry. XOMA currently has a PEG ratio of 0.9. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for XOMA relative to other companies in the Biotechnology industry. Currently, XOMA has a P/S ratio of 10.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for XOMA in comparison with other companies in the Biotechnology industry. Currently, XOMA has a P/B value of 6.9. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |